Baudax Blo®

Company Overview

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for patients in rare disease settings. We believe we can create value for healthcare providers, patients, and shareholders through our portfolio of products, which also includes a robust pipeline of product candidates. In addition, we continue to evaluate acquisition and licensing opportunities that align with our core acute care focus.

Our product candidate pipeline includes early-stage product candidates, including a recently acquired TCR Treg platform, two novel neuromuscular blocking agents (NMBAs), and a related proprietary chemical reversal agent.

Baudax Bio Announces Corporate Update

Oct 18 2023, 8:00 AM EDT

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

Sep 28 2023, 8:00 AM EDT

Investor Relations

LifeSci Advisors Mike Moyer mmoyer@lifesciadvisors.com

Management Team

Gerri Henwood

President & Chief Executive Officer

Yong Chan Kim, Ph.D.

Chief Scientific Officer

Mike Choi

VP, Financial Planning & Analysis

Randall Mack

Senior Consultant, Development

Stewart McCallum

Consultant, Chief Medical Officer

Diane Myers

Senior Consultant, Regulatory & Quality

Natalie McAndrew

Consultant, Principle Accounting Officer

Baudax Bio, Inc.

490 Lapp Road Malvern, PA 19355

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.